biotech
Dementia is a major healthcare problem across the globe. It is estimated by medical professionals that someone develops some form of dementia every three seconds, and about 55-60 million people...
Published:
With a recession likely on the way, health care is the place to be in 2023 for long-term investors looking for growth and income. These seven industry leaders offer solid total return potential in a...
Published:
Last Updated:
Pharmaceutical giant Merck has offered to acquire biopharma firm Imago Biosciences for $1.35 billion.
Published:
One big Wall Street name thinks it has found a big winner in this gene-editing company, and the stock could benefit greatly going forward.
Published:
Here are a few big biopharma names on which Wall Street is growing more bearish.
Published:
A few big biopharma names were on the move Tuesday morning, and analysts were taking their shot at them.
Published:
Here is a look of a few of the biggest clinical trial and FDA updates in regards to psychedelics to watch for in 2022.
Published:
Biotechnology was a huge laggard last year, but Truist Securities is out with its five top picks for 2022 that could see some sensational performance this year. Portfolio managers favor these...
Published:
Shares of five top established and mature biotechnology and pharmaceutical companies have been hit hard and are offering some of the best entry points in months. The stocks also are rated Buy at top...
Published:
Health care is poised to benefit from a shift toward more defensive sectors. These five stocks have strong balance sheets, attractive dividend yields and improved cost structures. With even moderate...
Published:
In this massively overbought market, health care stocks could benefit from a shift toward more defensive sectors. These five offer strong balance sheets, attractive dividend yields and improved cost...
Published:
While not suited for conservative income investors, these two top biotech stocks could have huge total return potential and offer investors with a touch more risk tolerance some very tempting entry...
Published:
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or...
Published:
These are four stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or...
Published:
Here are five biotech stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, these are not penny...
Published: